These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 34839327)

  • 21. Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention.
    Michaeli DT; Michaeli JC; Albers S; Boch T; Michaeli T
    Am J Cardiovasc Drugs; 2023 Sep; 23(5):477-495. PubMed ID: 37486464
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Familial Partial Lipodystrophy (FPLD): Recent Insights.
    Bagias C; Xiarchou A; Bargiota A; Tigas S
    Diabetes Metab Syndr Obes; 2020; 13():1531-1544. PubMed ID: 32440182
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Lipodystrophies].
    Fardet L; Vigouroux C; Capeau J
    Rev Med Interne; 2013 Oct; 34(10):614-22. PubMed ID: 23287278
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Type 1 diabetes associated with acquired generalized lipodystrophy and insulin resistance: the effect of long-term leptin therapy.
    Park JY; Chong AY; Cochran EK; Kleiner DE; Haller MJ; Schatz DA; Gorden P
    J Clin Endocrinol Metab; 2008 Jan; 93(1):26-31. PubMed ID: 17940115
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Therapy resistant diabetes mellitus and lipodystrophy: leptin therapy leads to improvement].
    Jazet IM; Jonker JT; Wijngaarden MA; Lamb H; Smelt AH
    Ned Tijdschr Geneeskd; 2013; 157(4):A5482. PubMed ID: 23343738
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Volanesorsen: First Global Approval.
    Paik J; Duggan S
    Drugs; 2019 Aug; 79(12):1349-1354. PubMed ID: 31301033
    [TBL] [Abstract][Full Text] [Related]  

  • 27. ANGPTL3 and Apolipoprotein C-III as Novel Lipid-Lowering Targets.
    Akoumianakis I; Zvintzou E; Kypreos K; Filippatos TD
    Curr Atheroscler Rep; 2021 Mar; 23(5):20. PubMed ID: 33694000
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lipodystrophies in non-insulin-dependent children: Treatment options and results from recombinant human leptin therapy.
    Calcaterra V; Magenes VC; Rossi V; Fabiano V; Mameli C; Zuccotti G
    Pharmacol Res; 2023 Jan; 187():106629. PubMed ID: 36566927
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A controlled-release mitochondrial protonophore reverses hypertriglyceridemia, nonalcoholic steatohepatitis, and diabetes in lipodystrophic mice.
    Abulizi A; Perry RJ; Camporez JPG; Jurczak MJ; Petersen KF; Aspichueta P; Shulman GI
    FASEB J; 2017 Jul; 31(7):2916-2924. PubMed ID: 28330852
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comprehensive analysis of morbidity and mortality patterns in familial partial lipodystrophy patients: insights from a population study.
    Guidorizzi NR; Valerio CM; Viola LF; Veras VR; Fernandes VO; Lima GEDCP; Flor AC; Araújo JS; Gonçalves Muniz RB; Moreira RO; De Paula FJA; Zajdenverg L; Dantas JR; Godoy-Matos AF; Montenegro Júnior RM; Foss-Freitas MC
    Front Endocrinol (Lausanne); 2024; 15():1359211. PubMed ID: 38887266
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A subset of patients with acquired partial lipodystrophy developing severe metabolic abnormalities.
    Ozgen Saydam B; Sonmez M; Simsir IY; Erturk MS; Kulaksizoglu M; Arkan T; Hekimsoy Z; Cavdar U; Akinci G; Demir T; Altay CT; Mihci E; Secil M; Akinci B
    Endocr Res; 2019; 44(1-2):46-54. PubMed ID: 30182761
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Assessment of efficacy and safety of volanesorsen for treatment of metabolic complications in patients with familial partial lipodystrophy: Results of the BROADEN study: Volanesorsen in FPLD; The BROADEN Study.
    Oral EA; Garg A; Tami J; Huang EA; O'Dea LSL; Schmidt H; Tiulpakov A; Mertens A; Alexander VJ; Watts L; Hurh E; Witztum JL; Geary RS; Tsimikas S
    J Clin Lipidol; 2022; 16(6):833-849. PubMed ID: 36402670
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recombinant human leptin treatment in genetic lipodystrophic syndromes: the long-term Spanish experience.
    Araujo-Vilar D; Sánchez-Iglesias S; Guillín-Amarelle C; Castro A; Lage M; Pazos M; Rial JM; Blasco J; Guillén-Navarro E; Domingo-Jiménez R; del Campo MR; González-Méndez B; Casanueva FF
    Endocrine; 2015 May; 49(1):139-47. PubMed ID: 25367549
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dunnigan lipodystrophy syndrome: French National Diagnosis and Care Protocol (PNDS; Protocole National de Diagnostic et de Soins).
    Mosbah H; Donadille B; Vatier C; Janmaat S; Atlan M; Badens C; Barat P; Béliard S; Beltrand J; Ben Yaou R; Bismuth E; Boccara F; Cariou B; Chaouat M; Charriot G; Christin-Maitre S; De Kerdanet M; Delemer B; Disse E; Dubois N; Eymard B; Fève B; Lascols O; Mathurin P; Nobécourt E; Poujol-Robert A; Prevost G; Richard P; Sellam J; Tauveron I; Treboz D; Vergès B; Vermot-Desroches V; Wahbi K; Jéru I; Vantyghem MC; Vigouroux C
    Orphanet J Rare Dis; 2022 Apr; 17(Suppl 1):170. PubMed ID: 35440056
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of efficacy and safety of antisense inhibition of apolipoprotein C-III with volanesorsen in patients with severe hypertriglyceridemia.
    D'Erasmo L; Gallo A; Di Costanzo A; Bruckert E; Arca M
    Expert Opin Pharmacother; 2020 Oct; 21(14):1675-1684. PubMed ID: 32646313
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hypertriglyceridemia.
    Chait A
    Endocrinol Metab Clin North Am; 2022 Sep; 51(3):539-555. PubMed ID: 35963627
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lipodystrophy: lessons in lipid and energy metabolism.
    Simha V; Garg A
    Curr Opin Lipidol; 2006 Apr; 17(2):162-9. PubMed ID: 16531753
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Lipodystrophy. Mechanisms, clinical presentation, therapy].
    Miehle K; Stumvoll M; Fasshauer M
    Internist (Berl); 2011 Apr; 52(4):362, 364-6, 368-70 passim. PubMed ID: 21424143
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Monogenic forms of lipodystrophic syndromes: diagnosis, detection, and practical management considerations from clinical cases.
    Vatier C; Vantyghem MC; Storey C; Jéru I; Christin-Maitre S; Fève B; Lascols O; Beltrand J; Carel JC; Vigouroux C; Bismuth E
    Curr Med Res Opin; 2019 Mar; 35(3):543-552. PubMed ID: 30296183
    [TBL] [Abstract][Full Text] [Related]  

  • 40. APOC3 inhibition with volanesorsen reduces hepatic steatosis in patients with severe hypertriglyceridemia.
    Prohaska TA; Alexander VJ; Karwatowska-Prokopczuk E; Tami J; Xia S; Witztum JL; Tsimikas S
    J Clin Lipidol; 2023; 17(3):406-411. PubMed ID: 37164837
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.